<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Coronary heart disease.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Finnish Medical Society Duodecim. Coronary heart disease. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley &amp; Sons; 2010 Apr 24&amp;nbsp;[Various]. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Finnish Medical Society Duodecim. Coronary heart disease (CHD): symptoms, diagnosis and treatment. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley &amp;amp; Sons; 2008 Mar 20 [Various]. [18 references]&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Acute coronary occlusion without myocardial infarction  (411.81); Acute myocardial infarction of unspecified site, episode of care unspecified  (410.90); Aortocoronary bypass for heart revascularization, not otherwise specified  (36.10); Chest pain, unspecified  (786.50); Chronic total occlusion of coronary artery  (414.2); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Diagnostic ultrasound of heart  (88.72); Electrocardiogram  (89.52); General physical examination  (89.7); Loss of weight  (783.21); Obesity, unspecified  (278.00); Other and unspecified angina pectoris  (413.9); Unspecified disorder of lipoid metabolism  (272.9)"/><FieldValue Value="MSH: Acute Coronary Syndrome ; Adrenergic beta-Antagonists ; Alcohol-Related Disorders ; Angina Pectoris ; Angina, Stable ; Angioplasty, Balloon, Coronary ; Angiotensin-Converting Enzyme Inhibitors ; Antioxidants ; Aspirin ; Biological Markers ; Blood Chemical Analysis ; Calcium Channel Blockers ; Cardiac Surgical Procedures ; Chest Pain ; Coronary Angiography ; Coronary Artery Bypass ; Coronary Disease ; Diet Therapy ; Echocardiography ; Echocardiography, Stress ; Electrocardiography ; Exercise Test ; Folic Acid ; Hormone Replacement Therapy ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hypercholesterolemia ; Hypertension ; Life Style ; Lipid Metabolism Disorders ; Medical History Taking ; Myocardial Infarction ; Myocardial Perfusion Imaging ; Myocardial Revascularization ; Nitrates ; Obesity ; Percutaneous Coronary Intervention ; Physical Examination ; Platelet Aggregation Inhibitors ; Postmenopause ; Premenopause ; Radionuclide Imaging ; Risk Factors ; Risk Reduction Behavior ; Smoking ; Smoking Cessation ; Stents ; Ticlopidine ; Tomography Scanners, X-Ray Computed ; Tomography, X-Ray Computed ; Weight Loss "/><FieldValue Value="MTH: Acute myocardial infarction ; Adrenergic beta-Antagonists ; Angina Pectoris ; Angioplasty, Balloon, Coronary ; Angiotensin-Converting Enzyme Inhibitors ; Antioxidants ; Aspirin ; Biological Markers ; Blood Chemical Analysis ; Body Weight decreased ; Calcium Channel Blockers ; Cardiac enzymes measurement ; Cardiac Surgery procedures ; Cessation of smoking ; Chest Pain ; Computed Tomography Scanning Systems ; Coronary angiography ; CORONARY ARTERIOSCLEROSIS ; Coronary Artery Bypass Surgery ; Coronary heart disease ; Diet therapy ; Echocardiography ; Electrocardiography ; Exercise stress test ; Folic Acid ; Hormone replacement therapy ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hypercholesterolemia ; Hypertensive disease ; Life Style ; Lipid Metabolism Disorders ; Measurement of serum lipid level ; Myocardial Infarction ; Nitrates ; Obesity ; Percutaneous Coronary Intervention ; physical examination ; Plain chest X-ray ; Plasma Glucose Measurement ; Platelet Aggregation Inhibitors ; Premenopause ; Radionuclide Imaging ; risk factors ; Serum cholesterol measurement ; Serum HDL cholesterol measurement ; Serum LDL cholesterol measurement ; Serum Triglyceride Measurement ; Smoking ; Stable angina ; Stent, device ; Treadmill, device ; Troponin I measurement ; Troponin T Assay ; X-Ray Computed Tomography "/><FieldValue Value="PDQ: acetylsalicyclic acid ; biological markers ; computed tomography ; folic acid ; obesity ; radionuclide imaging "/><FieldValue Value="SNOMEDCT_US: Acute coronary insufficiency  (194823009); Acute coronary syndrome  (394659003); Acute myocardial infarction  (57054005); Alcohol-induced organic mental disorder  (29212009); Angina pectoris  (194828000); Angina pectoris  (225566008); Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); Aspirin  (387458008); Aspirin  (7947003); beta-Blocking agent  (33252009); beta-Blocking agent  (373254001); Blood chemistry  (166312007); Calcium channel blocker  (373304005); Calcium channel blocker  (48698004); Cardiac enzymes/isoenzymes measurement  (74500006); Chest pain  (29857009); Cholesterol reduction program  (310876000); Clinical chemistry analyzer  (11987000); Clopidogrel  (108979001); Clopidogrel  (386952008); Computerized axial tomography  (77477000); Coronary angiography  (33367005); Coronary arteriosclerosis  (53741008); Coronary artery bypass graft  (232717009); Coronary artery bypass graft  (67166004); Coronary artery bypass graft  (90205004); Coronary artery stent  (705643001); CT angiography  (418272005); CT angiography of coronary arteries  (419545005); Disorder of lipid metabolism  (267431006); Echocardiography  (40701008); Electrocardiographic procedure  (29303009); Exercise tolerance test  (165079009); Fasting lipid profile  (252150008); Folic acid  (6247001); Folic acid  (63718003); Glucose measurement, plasma  (72191006); HMG-CoA reductase inhibitor  (372912004); HMG-CoA reductase inhibitor  (96302009); Hormone replacement therapy  (266717002); Hypercholesterolemia  (13644009); Hypertensive disorder  (38341003); Life style  (134436002); Life style  (60134006); Measurement of serum lipid level  (271244005); Measurement of serum triglyceride level  (271245006); Myocardial infarction  (22298006); Myocardial revascularization  (174911007); Myocardial revascularization  (275227003); Myocardial revascularization  (81266008); Nitrate salt  (89119000); Nuclear medicine imaging procedure  (373205008); Obesity  (414915002); Obesity  (414916001); Operation on heart  (64915003); Percutaneous coronary intervention  (415070008); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Plain chest X-ray  (399208008); Risk factor  (80943009); Serum HDL cholesterol measurement  (166832000); Serum LDL cholesterol measurement  (166833005); Stable angina  (233819005); Stent  (65818007); Ticlopidine  (108971003); Ticlopidine  (386950000); Treadmill  (1211003); Troponin I measurement  (121870001); Troponin T measurement  (121871002); Weight decreased  (161832001); Weight decreased  (262285001); Weight decreased  (89362005)"/><FieldValue Value="SPN: STENT, CORONARY ; SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED "/><FieldValue Value="UMD: Analyzers, Laboratory, Clinical Chemistry  (15-551); Catheters, Vascular, Angioplasty, Balloon, Coronary Perfusion  (17-521); Exercisers, Aerobic, Treadmill  (14-141); Monitoring Systems, Physiologic, Stress Exercise  (12-649); Physiologic Monitor Modules, Electrocardiography  (20-771); Probes, Gamma Radiation Detection  (23-068); Radiographic Systems  (18-429); Radiographic Systems, Digital, Chest  (18-431); Radiographic/Fluoroscopic Systems, Angiography/Interventional  (16-597); Scanning Systems, Computed Tomography  (13-469); Scanning Systems, Ultrasonic, Cardiac  (17-422); Stents  (15-784); Stents, Vascular, Coronary  (18-237)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Coronary heart disease (CHD), including&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Chronic stable angina &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acute coronary syndrome &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Critical Care" /><FieldValue Value="Emergency Medicine" /><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Pharmacology" /><FieldValue Value="Radiology" /><FieldValue Value="Thoracic Surgery" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Health Care Providers" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Evidence-Based Medicine Guidelines collect, summarize, and update the core clinical knowledge essential in general practice. The guidelines also describe the scientific evidence underlying the given recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Persons with suspected or confirmed coronary heart disease, including those with stable angina&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Evaluation/Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Physical examination &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Electrocardiogram &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Laboratory tests (e.g., serum cholesterol, high-density lipoprotein [HDL] cholesterol, triglycerides, low-density lipoprotein [LDL] cholesterol) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise test &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Imaging studies&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Chest x-ray &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Echocardiography &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Radionuclide imaging (myocardial perfusion scan) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Exercise echocardiography &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Coronary angiography &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Coronary computed tomography (CT) angiography &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diagnostic problems in women: premenopausal and menopausal women &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Treatment/Management&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Risk factor reduction (e.g., smoking, alcohol, hypertension, hyperlipidemia, obesity) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacotherapy&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Aspirin &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Clopidogrel &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Angiotensin converting enzyme (ACE) inhibitor &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Statins &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Beta-blockers &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Calcium-channel blockers &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Long-acting nitrate &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Revascularization&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Percutaneous transluminal coronary angioplasty (PTCA) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Percutaneous coronary intervention (PCI) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Coronary artery bypass graft surgery (CABG) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Hormone replacement therapy, antioxidant therapy, and folic acid were considered, but no evidence exists for proof of their efficacy.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Sensitivity and specificity of diagnostic tests &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Revascularization rate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Coronary events &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Mortality rate &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The evidence reviewed was collected from the Cochrane database of systematic reviews and the Database of Abstracts of Reviews of Effectiveness (DARE). In addition, the Cochrane Library and medical journals were searched specifically for original publications.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Classification of the Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Grading the Quality of Evidence&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Code&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;High&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is very unlikely to change confidence in the estimate of effect.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Several high-quality studies with consistent results &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;In special cases: one large, high-quality multi-centre trial &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Moderate&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;One high-quality study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Several studies with some limitations &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;One or more studies with severe limitations &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Very Low&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Any estimate of effect is very uncertain.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;No direct research evidence &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;One or more studies with very severe limitations &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group (modified by the EBM Guidelines Editorial Team).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Not stated" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The levels of evidence [A-D] supporting the recommendations are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Essentials&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A detailed symptom history, physical examination, 12 lead electrocardiogram (ECG), laboratory tests and a careful assessment of risk factors (see table 1 below) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A variety of different tools have been introduced to predict the risk of coronary heart disease (CHD), for example the Systematic Coronary Risk Evaluation (SCORE) calculator. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If the symptoms and the estimated risk score are suggestive of CHD an exercise test is indicated (see the Finnish Medical Society Duodecim guideline &quot;Exercise Stress Test&quot;). An exercise test may also be used to assess the severity of the disease and, in some cases, to monitor the treatment response as well as to assess the patient's functional capacity. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The diagnosis of CHD may be further confirmed by the observed response to the prescribed drug therapy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The treatment of CHD consists of both symptom management, which is provided by drug therapy and if necessary by invasive interventions, as well as of risk factor reduction.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Optimal drug therapy combined with lifestyle changes is crucial for the prognosis, whereas invasive interventions mainly aim to improve symptoms. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Causes and Clinical Manifestation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The accumulation of low density lipoprotein (LDL) cholesterol in the intima (inner lining) of the arteries, and associated inflammatory reactions with a multitude of mechanisms will gradually lead to the formation of atherosclerotic plaques within the arterial tree, including the coronary arteries. The risk of developing CHD is increased not only by a high LDL cholesterol concentration but also by other risk factors (see table 1 below). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chronic stable angina and acute coronary syndrome (see the Finnish Medical Society Duodecim guideline &quot;Acute Coronary Syndrome and Myocardial Infarction&quot;) are clinical manifestations of CHD. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 1. Risk Factors of CHD&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table 1. Risk Factors of CHD&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Classic Risk Factors&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Others&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High blood LDL cholesterol concentration&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Low blood high-density lipoprotein (HDL) cholesterol concentration&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Smoking&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High blood triglyceride concentration&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Raised blood pressure&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Insulin resistance&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Diabetes&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Overweight&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Age&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Physical inactivity&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Genetic factors&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Psychological factors&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Factors associated with blood clotting and flow&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Nutritional factors&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Infections&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Atherosclerotic plaques in the coronary arteries obstruct the blood flow thus reducing the oxygen supply to the myocardium which in turn produces the typical symptom of CHD, chest pain (angina pectoris). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Other symptoms include exertional dyspnoea, fatigue on exertion, arrhythmias and heart failure. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Differential diagnosis of chest pain: See Table 2 below. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 2. Non-Ischaemic Causes of Chest Pain&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table 2. Non-Ischaemic Causes of Chest Pain&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Disease&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Differentiating Signs and Symptoms&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Aortic dissection&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Sudden intense chest pain &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Blood pressure may be low and pulses asymmetrical &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;New-onset aortic valve regurgitation &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Dissection may obstruct the origins of coronary arteries with signs of impending infarction &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Broad mediastinum on chest x-ray &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Acute pulmonary embolism&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Dyspnoea and tachypnoea as the principal symptoms &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Chest pain in about half of patients &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Tachycardia, right bundle branch block (RBBB), low blood pressure in extensive pulmonary embolism &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Chest x-ray is often normal &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Partial pressure of oxygen in arterial blood (PaO&lt;sub&gt;2&lt;/sub&gt;) decreased or normal, partial pressure of carbon dioxide in the blood (PaCO&lt;sub&gt;2&lt;/sub&gt;) decreased or normal &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;D-dimer assay positive; negative result excludes pulmonary embolism with high probability &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Spontaneous pneumothorax,&lt;br /&gt;&#xD;&#xA;            tension pneumothorax&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Dyspnoea, chest pain &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Quiet breath sounds on auscultation &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Chest x-ray will confirm diagnosis &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Oesophageal tear, perforated ulcer&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Chest pain, upper abdominal pain &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Pericarditis, myocarditis &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Pain is usually retrosternal and is sharp or tearing in nature &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;The pain is aggravated by inspiration, coughing and changing of position &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;A friction rub may be heard &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;ST&amp;ndash;T changes with almost daily alternations &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Pleuritis&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Signs and symptoms of respiratory tract infection &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Stabbing chest pain, aggravated by inspiration and coughing &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Costochondral pain&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Pain on palpation &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Chest wall movements and breathing may aggravate the pain &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Oesophageal inflammation or spasm, dyspepsia&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Heartburn, chest pain, upper abdominal pain &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;May be worse in recumbent position and on exertion (reflux) &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;No ECG changes &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Relief from proton pump inhibitors (PPIs) &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Early herpes zoster&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;No ECG changes &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Rash appears within a few days &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Localised paraesthesia before the appearance of the rash &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Hyperventilation syndrome &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Strong feeling of lack of air &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Fast and deep breathing &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Cold limbs with tingling and numbness &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Dizziness, headache, dry mouth &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;PaCO&lt;sub&gt;2&lt;/sub&gt; decreased, PaO&lt;sub&gt;2&lt;/sub&gt; increased or normal &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Depression&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Continuous feeling of heaviness in the chest, no correlation to exercise &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;ECG normal &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Symptoms and Clinical Diagnosis&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Stable angina is a clinical diagnosis which indicates the repeated occurrence of chest pain, induced by an exercise level typical for the patient. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The pain is relieved by rest and shows no great daily variation, occurring at predictable levels of exercise (i.e., when the rate-pressure product exceeds the patient's personal threshold). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Typical angina pain&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Starts gradually during exertion, more quickly if the exertion is sudden, and becomes worse as the exertion continues. Sometimes continuing the exertion does not increase the pain but instead brings about relief (the walk-through angina phenomenon).&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Emotional stress may also provoke pain as the rate-pressure product increases. &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Is felt across the chest as widespread constrictive, heavy or tight pain that may make the person slow down or stop. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Is relieved in a few minutes by rest or glyceryl trinitrate. &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The pain may also radiate to the neck, jaw, arms, epigastric region or back. The sites of radiation usually stay fairly constant. The pain is often aggravated by cold, eating or smoking. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If the pain meets all of the above three characteristics, it is highly probable that the patient has typical angina. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If the pain only meets two of the above characteristics, the patient has atypical angina. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If the pain only meets one or none of the above characteristics, the patient is likely to have non-cardiac chest pain.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The characteristics of non-cardiac chest pain include:&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;The patient's exercise tolerance is usually normal. &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Pain occurs at rest and is sharp or stabbing in nature and may last for several hours or even days. &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;The location of pain may vary, and the pain sites are sometimes palpable. &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Pain is associated with chest wall movements. &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Glyceryl trinitrate does not help or takes more than 10 minutes to bring pain relief. &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;One in two patients with CHD presents with typical symptoms.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The diagnostic accuracy of symptom history is more reliable in men than in women of less than 50 years of age. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The probability of CHD in a male patient over 55 years with typical symptoms is 90%. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Classification of chest pain (CCS, Canadian Cardiovascular Society &amp;ndash; corresponds to the previously used New York Heart Association [NYHA] classification): see table 3 below. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 3. Classification of Angina (Canadian Cardiovascular Society)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table 3. Classification of Angina (Canadian Cardiovascular Society)&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Angina Class&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Activity Provoking Chest Pain&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Exercise Tolerance&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CCS-Class 1&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Only strenuous exercise &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;120 W or more&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CCS-Class 2&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Walking briskly or uphill &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;80-120 W&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CCS-Class 3&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Walking on level at normal pace &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;20-80 W&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;CCS-Class 4&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Rest, talking or dressing&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Less than 20 W&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Investigations&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Physical Examination&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;In most patients, the physical examination is totally normal! &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The presence of vascular bruits should be checked as CHD patients often have concomitant carotid artery disease and/or generalised arteriosclerotic disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;S3 and a soft mitral regurgitant murmur are signs of impaired cardiac function. They may be a transient functional effect caused of prolonged ischaemia or only be audible during exercise. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Electrocardiogram (ECG)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The ECG is usually normal at rest. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reversible ST segment depression that appears during pain and disappears as the pain subsides is highly suggestive of CHD. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A Q wave, signifying a prior myocardial infarction (MI), is suggestive of CHD. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ST-T changes are a sensitive but non-specific finding. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Fascicular block and bundle branch block (left anterior hemiblock [LAHB], right bundle branch block, and left bundle branch block [LBBB]) are more common in patients with multivessel CHD, but the finding is not specific. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Laboratory Tests&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Risk factor investigations: serum cholesterol, HDL cholesterol, triglycerides, LDL cholesterol, glucose &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blood counts, platelets and creatinine level are also checked. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A 2-hour oral glucose tolerance test should be carried out if CHD is confirmed or if metabolic syndrome is suspected. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Brain natriuretic peptide (BNP) levels should be determined to diagnose heart failure if signs and symptoms suggestive of failure are present. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exercise Test&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;An exercise test is indicated in most cases for the confirmation of the diagnosis and for the assessment of disease severity. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For details, (see the Finnish Medical Society Duodecim guideline &quot;Exercise Stress Test&quot;). &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Imaging Studies&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Chest x-ray&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Heart size, pulmonary congestion, signs of heart failure, valvular calcification and other causes of chest pain &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Echocardiography (see the Finnish Medical Society Duodecim guideline &quot;Echocardiography as an Outpatient Procedure.&quot;)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Recommended when&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;A prior MI is noted (i.e., pathological Q waves in an ECG or signs of heart failure). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;A strong systolic murmur is present (e.g., suggestive of mitral regurgitation). &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Frequent ventricular ectopic beats are noted. &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Radionuclide imaging (myocardial perfusion scan)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The sensitivity is higher than that of an exercise test but the specificity is roughly the same. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;May be carried out if&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;An exercise test is not diagnostic but CHD is very likely. &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;The patient is physically handicapped. &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;An ECG abnormality (left bundle branch block, left ventricular hypertrophy [LVH], Wolff-Parkinson-White Syndrome (WPW), electronically paced ventricular rhythm) interferes with the interpretation of the exercise test. &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise echocardiography&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Ischaemia induces myocardial wall motion abnormalities, which can be detected with high quality ultrasound equipment. The test is more sensitive and more accurate than an exercise test but requires an experienced operator. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;May be considered when ECG abnormalities (e.g., LBBB) interfere with the interpretation of an exercise test. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Coronary angiography&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;For details, see the Finnish Medical Society Duodecim guideline &quot;Diagnostic Coronary Angiography.&quot; &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Coronary computed tomography (CT) angiography allows noninvasive imaging of the coronary arteries.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The quality and results of this investigation are continually improving as new equipment and methods are developed. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Coronary CT angiography should be reserved for patients whose likelihood of having CHD is small, and the indications for the investigation are therefore more restricted than those for conventional angiography. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Special Diagnostic Problems in Women&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;In women, CHD is diagnosed on average 10 years later than in men. The incidence of CHD increases noticeably after menopause. At the age of 70&amp;ndash;79 years, the gender difference both in the incidence and mortality due to CHD is levelled out. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The risk factors of CHD are the same for both sexes. Women who develop CHD before menopause have more risk factors than those who develop the disease at a later age. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is more difficult to diagnose CHD in women than in men.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The symptoms are different; in women, the chest pain is more often atypical and the disease may only manifest itself as dyspnoea, exhaustion, malaise or nausea on exertion. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Premenopausal women present with chest discomfort more often than men. On the other hand, CHD is diagnosed in only one in two premenopausal women with typical angina pain. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;After menopause, the diagnostic accuracy of symptoms improves markedly. In women aged 65&amp;ndash;70 years, the diagnostic accuracy of chest pain is similar to that in men. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If CHD develops in a middle-aged woman she is likely to have several risk factors: smoking, dyslipidaemia, type 2 diabetes, hypertension. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The predictive value of exercise test (see the Finnish Medical Society Duodecim guideline &quot;Exercise Stress Test&quot;) is worse in women. The number of false-positive test results is high in premenopausal women.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Ischaemic ST-segment depression that appears at a low heart rate and lasts several minutes after the cessation of exercise is suggestive of significant CHD. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;If the targeted maximum heart rate is reached and no ST segment changes appear, the probability of a significant CHD is low. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;A slight, upsloping ST segment depression that occurs at a high heart rate and rapidly disappears in rest is a typical false positive finding. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;In problematic cases, further investigations are indicated (myocardial perfusion scan and coronary angiography). &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Before menopause, the specificity of radionuclide imaging may be higher than that of the conventional exercise test. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Management of CHD Risk Factors&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Minimizing all risk factors has a marked effect on prognosis as it slows down the progress of atherosclerosis and prevents the development of an MI. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Stopping smoking (see the Finnish Medical Society Duodecim guideline &quot;Smoking Cessation&quot;) is very important. The risk of an MI is 3-fold in smokers and even higher in women (Ounpuu, Negassa, &amp;amp; Yusuf, 2001). Alcohol consumption should also be limited to moderate amounts (see the Finnish Medical Society Duodecim guideline &quot;Brief Interventions for Heavy Use of Alcohol&quot;). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hypertension should be treated. The target level of below 140/85 mmHg should always be achieved. The target in patients with diabetes is below 130/80 mmHg, especially if diabetes is associated with renal complications. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The management of hyperlipidaemia (see the Finnish Medical Society Duodecim guideline &quot;Treatment of Dyslipidaemias&quot;) requires treatment with a statin. The target levels given below are only meant as a guideline. Statins not only reduce blood lipid concentrations (Pitt et al., 1999) but also have an effect on coronary endothelial dysfunction, the inflammatory reactions and blood clotting (Scandinavian Simvastatin Survival Study Group, 1994). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recommendations:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Serum LDL cholesterol &amp;lt;2.5 mmol/l; optimal level &amp;lt;2.0 mmol/l. According to current scientific knowledge, drug therapy is almost always justified. In patients with diabetes and in high-risk patients, the target level should be even lower (serum LDL &amp;lt;1.6&amp;ndash;1.8 mmol/l). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Other targets should also be noted: serum cholesterol &amp;lt;4.5 mmol/l, serum triglycerides &amp;lt;2.0 mmol/l and serum cholesterol/serum HDL &amp;lt;4.0, serum HDL &amp;gt;1.0 mmol/l. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treating obesity&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;If the patient's body mass index (BMI) is higher than 28 and the waist circumference &amp;gt;100 centimeter (cm) in men, or &amp;gt;90 cm in women, weight reduction is indicated. The goal is to achieve a body mass index &amp;lt;25 and a waist circumference &amp;lt;94 cm in men and &amp;lt;80 cm in women. Abdominal obesity (high waist-to-hip ratio) signifies a particularly high risk (Yusuf et al., 2005) &lt;strong&gt;[B]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who have had an MI are often found to have a slightly increased fasting blood glucose concentration, impaired glucose tolerance or diabetes. If the 2-hour oral glucose tolerance test is normal, a fasting glucose measurement at the annual follow-up visit should suffice. Should the glucose tolerance test results be abnormal, the patient may need medication and more frequent follow-up visits in addition to exercise and dietary advice. The target glycosylated hemoglobin (HbA1c) is &amp;lt;6.5%. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Regular exercise improves not only the sense of well being but also the prognosis, by reducing risk factors (Taylor et al., 2004; Jolliffe et al., 2001) &lt;strong&gt;[A]&lt;/strong&gt;. Physical activity also plays a part in primary prevention (Murphy et al., 2002) &lt;strong&gt;[C]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Sudden and strenuous physical activity should be avoided. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Based on a randomised secondary prevention study (HERS) and a primary prevention study (Women's Health Initiative [WHI], Rossouw et al., 2002) &lt;strong&gt;[A]&lt;/strong&gt;, hormone replacement therapy offers no benefit in the prevention of CHD. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Antioxidant therapy with vitamin E had no beneficial effect in the HPS study (Heart Protection Study Collaborative Group, 2002) in the prevention of CHD, and neither did vitamins A and C. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Inclusion of fish in the diet at least once weekly or the use of omega 3 fatty acids have produced positive effects in secondary prevention and may be considered, even though there is no clear evidence that they influence prognosis (Hooper et al., 2004) &lt;strong&gt;[C]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Folic acid (and vitamins B&lt;sub&gt;6&lt;/sub&gt; and B&lt;sub&gt;12&lt;/sub&gt;) lowers serum homocysteine concentration. According to current scientific knowledge, however, lowering increased homocysteine concentrations is of no benefit (Mart&amp;iacute;-Carvajal et al., 2009) &lt;strong&gt;[B]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Pharmacotherapy: Aims and Modes of Action&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Efficient secondary prevention usually includes aspirin, a beta-blocker, a statin and an angiotensin-converting enzyme (ACE) inhibitor. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In CHD, effective pharmacotherapy is usually the only treatment needed if the symptoms are mild (Boden et al., 2007). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Aspirin&lt;/strong&gt; decreases platelet aggregation and thus reduces the risk of acute coronary events. Aspirin is recommended for all patients with CHD at a dose of 100&amp;ndash;250 mg/day, unless it is contraindicated (Antithrombotic Trialists' Collaboration, 2002). Patients allergic to aspirin may use clopidogrel. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Clopidogrel&lt;/strong&gt; also reduces platelet aggregation. As clopidogrel and aspirin inhibit platelet function through different surface receptors their combined use has an additive effect.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Clopidogrel is used in the treatment of acute coronary syndrome; both during the acute hospital phase and in the continued treatment (9&amp;ndash;12 months) after the acute event. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;After the insertion of a coronary stent, clopidogrel significantly decreases the incidence of stent thrombosis and should be included in the medication. The treatment is continued for 3 to 12 months depending on the case. The treatment period is shorter when stenting is carried out for occlusion that only caused stable angina, but after acute coronary syndrome the treatment period is 12 months. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Clopidogrel does not noticeably improve prognosis in chronic CHD (Squizzato et al., 2011; Bhatt et al., 2006) &lt;strong&gt;[B]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;An &lt;strong&gt;ACE inhibitor&lt;/strong&gt; should be included in the medication of patients who have had an MI or have left ventricular systolic failure or diabetes. An ACE inhibitor is also recommended for patients with CHD (Al-Mallah et al., 2006) &lt;strong&gt;[A]&lt;/strong&gt; or other atherosclerotic vascular disease.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;ACE inhibitors reduce the symptoms and cardiac events that are associated with ischaemic heart failure. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;It has been suggested that ACE inhibitors may in some way slow down the progress of atherosclerosis in the arterial walls. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The recommended maintenance doses should be used (ramipril 10 mg/day, enalapril 20 [&amp;ndash;40] mg/day, lisinopril 20 [&amp;ndash;40] mg/day) or the highest tolerated doses (adverse effects, hypotension). &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Statins&lt;/strong&gt; reduce cholesterol synthesis in the liver, blood LDL cholesterol concentration and the accumulation of LDL cholesterol on the vascular walls. Moreover, statins improve the functioning of the inner lining of the arteries, suppress blood clotting and interfere with inflammatory and immune responses. In patients with CHD, statins reduce the rate of both reinfarction and deaths (Baigent et al., 2005; Dale et al., 2006; Costa et al., 2006; Prospective Studies Collaboration, 2007) &lt;strong&gt;[A]&lt;/strong&gt;. Drug therapy and targets, see the Finnish Medical Society Duodecim guideline &quot;Treatment of Dyslipidaemias.&quot; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Beta blockers&lt;/strong&gt; lower heart rate and blood pressure and thus decrease myocardial oxygen consumption during exercise and often relieve chest pain.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;After MI, beta blockers significantly decrease the risk of reinfarction and death (Freemantle et al., 1999). &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The evidence on prognosis is not so convincing for patients with chronic CHD but no prior history of MI. However, beta blockade may be justified on the basis of symptom relief. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Adequate beta blockade has been achieved when the heart rate has reduced to 50&amp;ndash;60 bpm at rest. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Beta blockers are also the first-line antiarrhythmics in patients with CHD. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Calcium-channel blockers&lt;/strong&gt; have not been shown to reduce the frequency of cardiac events in patients with chronic CHD.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;However, verapamil and diltiazem have reduced the incidence of cardiac events post-MI in patients with intact left ventricular function. They can be used in symptomatic treatment, particularly when beta blockers are not suitable (Heidenreich et al., 1999) &lt;strong&gt;[B]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Amlodipine is the most studied dihydropyridine derivative. It does not appear to possess adverse circulatory effects even in patients with signs and symptoms of heart failure. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A &lt;strong&gt;long-acting nitrate&lt;/strong&gt; may be included in the medication regime if chest pain is frequent.&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The nitrate is administered at the time of day when symptoms occur most frequently, which is often during the daytime. The usual dose is 20&amp;ndash;40(&amp;ndash;60) mg/day. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;A nitrate patch can be used to treat nocturnal angina. The patch should be removed in the morning to avoid the development of nitrate tolerance. For the same reason a pause should be worked into the administration regime of long-acting nitrates, for example in the evening or at night. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Nitrates are only symptomatic therapy and are not needed if the patient is asymptomatic. They improve exercise tolerance but probably not the prognosis. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Short-acting glyceryl trinitrate (GTN), either as sublingual tablets or aerosol spray, is classically used for acute episodes. It should also be used prophylactically. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Indications for Additional Investigations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;In addition to pharmacotherapy, invasive investigations (coronary angiography) and treatment should be considered if&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;The patient's exercise tolerance and quality of life are clearly reduced despite maximal drug therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Signs of myocardial ischaemia are evident during an exercise test at a low exercise workload (&amp;lt;100 W) or a low heart rate (&amp;lt;120 bpm) or &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Signs of left ventricular dysfunction are present. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;See table 4 below &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Table 4. Noninvasive Risk Stratification in Patients with Stable CHD. Modified from the American College of Cardiology (ACC) and American Heart Association (AHA) guidelines.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table 4. Noninvasive Risk Stratification in Patients with Stable CHD&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Risk Category&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Risk Assessment Criteria&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;High risk (greater than 3% annual mortality rate)&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Left ventricular ejection fraction at rest less than 35%&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Highly abnormal exercise test (poor performance, hypotension, widespread ST segment depression developing at a low workload)&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Large or multiple perfusion defects or wall motion abnormalities noted in imaging studies that measure the extent of ischaemia (radionuclide imaging, perfusion magnetic resonance imaging [MRI], stress echocardiography) &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Intermediate risk (1&amp;ndash;3% annual mortality rate) &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Left ventricular ejection fraction at rest 35&amp;ndash;40%&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Abnormal exercise test but without signs of high risk&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Moderate perfusion defect or wall motion abnormality noted in imaging studies that measure the extent of ischaemia &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Low risk (less than 1% annual mortality rate) &lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Left ventricular ejection fraction at rest more than 50%&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Normal or slightly abnormal exercise test&lt;br /&gt;&#xD;&#xA;            &lt;br /&gt;&#xD;&#xA;            Normal or slightly abnormal findings noted in imaging studies that measure the extent of ischaemia &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;Source: Lammintausta et al. Hoitostrategian valinta vakaaoireisessa sepelvaltimotaudissa [The choice of treatment in stable CHD]. Publication: Heikkil&amp;auml; (ed.) Kardiologia [Cardiology], Duodecim Medical Publications Ltd, 2008, p. 410.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Revascularisation (PTCA and CABG)&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Coronary artery revascularisation may be performed either by balloon angioplasty (percutaneous transluminal coronary angioplasty, PTCA) followed by the placing of a metal stent into the coronary artery (percutaneous coronary intervention, PCI), or by coronary artery bypass graft surgery (CABG).&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Coronary artery patency is sustained better with stenting than with PTCA alone (Wessex Institute for Health Research and Development, 1998; Meads, Cummings, &amp;amp; Stevens, 1998) &lt;strong&gt;[B]&lt;/strong&gt;. Stenting has reduced the need for coronary surgery. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Drug-eluting stents are impregnated with a cell growth inhibitor that is slowly released into the surrounding tissues over several months. Drug-eluting stents have clearly reduced the frequency of restenosis and cardiovascular events compared with metal stents or PTCA alone, but drug-eluting stents may be associated with late thrombosis (Greenhalgh et al., 2010) &lt;strong&gt;[A]&lt;/strong&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The decision regarding the need for revascularisation and the preferred method (PCI/CABG) is based not only on the severity, location and number of coronary occlusions but also on the assessment of left ventricular function, potential valvular diseases, severity of symptoms and comorbidity (diabetes, renal disease).&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Stenosis of the left main coronary artery (LCA) warrants CABG. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;CABG is favoured in three vessel disease, left ventricular failure and diabetes. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Proximal stenoses of the left main branches are established indications for revascularisation, either with PCI or CABG depending on the clinical situation. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Left ventricular failure due to ischaemia is also an indication for revascularisation, either with PCI or CABG depending on the clinical situation. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The restoration of the patency in a complete occlusion with PCI shows variable success. Factors affecting the success rate include the age of the total occlusion (occlusions older than 3 months do not always retain their patency), technical problems associated with the procedure and also the experience of the cardiologist. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Single vessel disease, provided that the stenosis is not located proximally in a large coronary artery, has a favourable prognosis even with drug therapy, but substantial symptoms may justify revascularisation. In single or two vessel disease, PCI is often chosen. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;It appears that patients with diabetes continue to benefit more from a CABG. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The advantages of PCI include the short duration of treatment, shorter recovery period and faster return back to work. The more frequent need for later revascularisation compared with CABG may be considered a disadvantage. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Related Evidence&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Refer to the original guideline document for related evidence, including Cochrane reviews and other evidence summaries.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Classification of the Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; summary=&quot;Table: Grading the Quality of Evidence&quot; cellpadding=&quot;5&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Code&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Quality of Evidence&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Definition&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;A&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;High&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is very unlikely to change confidence in the estimate of effect.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Several high-quality studies with consistent results &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;In special cases: one large, high-quality multi-centre trial &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;B&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Moderate&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;One high-quality study &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Several studies with some limitations &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;C&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;One or more studies with severe limitations &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;D&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Very Low&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Any estimate of effect is very uncertain.&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Expert opinion &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;No direct research evidence &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;One or more studies with very severe limitations &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;GRADE (Grading of Recommendations Assessment, Development and Evaluation) Working Group (modified by the EBM Guidelines Editorial Team).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, Weaver WD. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2006 Apr 18;47(8):1576-83. [39 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16630993&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002 Jan 12;324(7329):71-86. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11786451&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267-78. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16214597&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20;354(16):1706-17. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16531616&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503-16. [46 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17387127&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006 May 13;332(7550):1115-24. [50 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16585050&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006 Jan 4;295(1):74-80. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16391219&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999 Jun 26;318(7200):1730-7. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10381708&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Greenhalgh J, Hockenhull J, Rao N, Dundar Y, Dickson RC, Bagust A. Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes. Cochrane Database Syst Rev. 2010;(5):CD004587. [99 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20464732&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6;360(9326):7-22. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12114036&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, Hlatky MA. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA. 1999 May 26;281(20):1927-36. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10349897&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, Durrington PN, Ness AR, Capps NE, Davey Smith G, Riemersma RA, Ebrahim SB. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev. 2004;(4):CD003177. [288 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15495044&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev. 2001;(1):CD001800. [111 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11279730&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Mart-Carvajal AJ, Sol I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2009;(4):CD006612. [129 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19821378&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Meads C, Cummings C, Stevens A. Coronary artery stents. Coventry (UK): West Midland Development and Evaluation Committee; 1998. 76 p.&amp;nbsp;(West Midland Development and Evaluation Committee Report; no. 9).&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Murphy M, Foster C, Sudlow C, Nicholas J, Mulrow C, Ness A, Pignone M. Cardiovascular disorders. Primary prevention. Clin Evid. 2002 Jun;(7):91-123. [171 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12230640&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ounpuu S, Negassa A, Yusuf S. INTER-HEART: A global study of risk factors for acute myocardial infarction. Am Heart J. 2001 May;141(5):711-21. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11320357&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LS. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. 1999 Jul 8;341(2):70-6. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10395630&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007 Dec 1;370(9602):1829-39. [25 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18061058&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Rossouw JE, Writing Group for the Women's Health Initiative Investigators, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12117397&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 Nov 19;344(8934):1383-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7968073&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Squizzato A, Keller T, Romualdi E, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev. 2011;(1):CD005158. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21249668&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, Skidmore B, Stone JA, Thompson DR, Oldridge N. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. Am J Med. 2004 May 15;116(10):682-92. [75 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15121495&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wessex Institute for Health Research and Development. Stents for coronary artery disease (CAD). York (UK): Wessex Institute for Health Research and Development; 1998. 33 p.&amp;nbsp;(Development and Evaluation Committee Report; no. 87).&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, Lang CC, Rumboldt Z, Onen CL, Lisheng L, Tanomsup S, Wangai P Jr, Razak F, Sharma AM, Anand SS, INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005 Nov 5;366(9497):1640-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16271645&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Concise summaries of scientific evidence attached to the individual guidelines are the unique feature of the Evidence-Based Medicine Guidelines. The evidence summaries allow the clinician to judge how well-founded the treatment recommendations are. The type of supporting evidence is identified and graded for select recommendations (see the &amp;quot;Major Recommendations&amp;quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate diagnosis and treatment of coronary heart disease&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Drug-eluting stents may be associated with late thrombosis.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Finnish Medical Society Duodecim. Coronary heart disease. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley &amp; Sons; 2010 Apr 24&amp;nbsp;[Various]. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2001 April 30 (revised 2010 Apr 23)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Finnish Medical Society Duodecim - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Finnish Medical Society Duodecim&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Editorial Team of EBM Guidelines&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Primary Author&lt;/em&gt;: Helena Kervinen&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Finnish Medical Society Duodecim. Coronary heart disease (CHD): symptoms, diagnosis and treatment. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley &amp;amp; Sons; 2008 Mar 20 [Various]. [18 references]&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline is included in &quot;EBM Guidelines. Evidence-Based Medicine&quot; available from Duodecim Medical Publications, Ltd, PO Box 713, 00101 Helsinki, Finland; e-mail: &lt;a href=&quot;mailto:info@ebm-guidelines.com&quot;&gt;info@ebm-guidelines.com&lt;/a&gt;; Web site: &lt;a href=&quot;http://www.ebm-guidelines.com&quot; title=&quot;EBM Guidelines Web site&quot;&gt;www.ebm-guidelines.com&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This summary was completed by ECRI on August 28, 2001. The information was verified by the guideline developer as of October 26, 2001. This summary was updated by ECRI on December 9, 2002, December 29, 2003, September 30, 2004, February 21, 2005, and July 13, 2006. This summary was updated by ECRI Institute on June 22, 2007 following the U.S. Food and Drug Administration (FDA) advisory on heparin sodium injection. This summary was updated by ECRI Institute on November 13, 2007. This summary was updated by ECRI Institute on March 14, 2008 following the updated FDA advisory on heparin sodium injection. This summary was updated by ECRI Institute on September 30, 2008. This summary was updated by ECRI Institute on January 5, 2010 following the U.S. Food and Drug Administration advisory on Plavix (Clopidogrel). This summary was updated by ECRI Institute on May 17, 2010 following the U.S. Food and Drug Administration advisory on Plavix (clopidogrel). This NGC summary was updated by ECRI Institute on May 10, 2011. This summary was updated by ECRI Institute on April 13, 2012 following the U.S. Food and Drug Administration advisories on Statin Drugs and Statins and HIV or Hepatitis C drugs.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
